EU to grant OGS patent for proteomics research processes
UK-based research and product development company Oxford GlycoSciences (OGS) is to be granted a patent by the European Patent Office covering the fundamental platform technology it has developed for use in conducting proteomics research.
UK-based research and product development company Oxford GlycoSciences (OGS) is to be granted a patent by the European Patent Office covering the fundamental platform technology it has developed for use in conducting proteomics research.
The patent gives OGS proprietary rights to computer-assisted methods and apparatus for identifying and isolating biomolecules in a biological sample. The patent is expected to be granted in the first quarter of this year; corresponding patents have already been granted to OGS in the US.
Ceo Dr David Ebsworth said: 'This patent is an affirmation that OGS is at the forefront of innovation in proteomics research.'
OGS has three distinct business units: proteomics; inherited storage disorders; and oncology. It has developed a patented technology platform, integrating high-throughput proteomics with genomics. OGS has proteomics collaborations with Bayer, Pioneer Hi-Bred/DuPont, GlaxoSmithKline, Pfizer, the Center for Drug Evaluation and Research of the US FDA, and the Cystic Fibrosis Foundation. OGS also has a joint venture, Confirmant Limited, to develop the Protein Atlas of the Human Genome.